Medifocus Inc. Announces Extension of Warrants
12 4월 2014 - 5:21AM
Marketwired
Medifocus Inc. Announces Extension of Warrants
TORONTO, ONTARIO--(Marketwired - Apr 11, 2014) - Medifocus Inc.
(Medifocus or the Company) (TSX-VENTURE:MFS)(OTCQX:MDFZF) is
pleased to announce that it has received approval from the TSX
Venture Exchange (the Exchange) to extend the expiry date of
2,449,997 outstanding common share purchase warrants issued
pursuant to the private placement announced April 9, 2010 (the
Warrants) by one year. The expiry date of the Warrants was extended
to April 24, 2014 in April, 2013 after having been extended to
April 24, 2013 in April, 2012. Each Warrant entitles the holder to
acquire one common share of Medifocus at a price of $0.50.
The Company will extend the term of the Warrants from April 24,
2014 to April 9, 2015. All other terms and conditions of the
Warrants (as amended) will remain unchanged and in full force and
effect.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive United States and international patent protection:
(i) The Endo-thermotherapy Platform-a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The United
States Food and Drug Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic
Hyperplasia (BPH) was developed based on the Endo-thermotherapy and
is currently generating revenue; and (ii) the Adaptive Phased Array
(APA) Microwave Focusing Platform, invented by the Massachusetts
Institute of Technology, licensed to Medifocus, directs precisely
focused microwave energy at tumor center to induce shrinkage or
eradication of tumors without undue harm to surrounding tissue.
Medifocus' APA 1000 Breast Cancer Treatment System, developed from
the APA technology platform, has received approval from the FDA and
Health Canada to conduct the pivotal Phase III clinical trials.
Medifocus believes that these two technology platforms can provide
the design basis for the development of multiple cancer treatment
systems for surface, subsurface and deep seated localized and
regional cancers. Please visit www.medifocusinc.com,
www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Medifocus Contact: John Mon, COOMedifocus,
Inc.410-290-5734JohnMon@medifocusinc.com Investor Relations
Contact:Robert GiordanoConsulting for Strategic Growth
1917-327-3938rgiordanonyc@gmail.com
Medifocus (CE) (USOTC:MDFZF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medifocus (CE) (USOTC:MDFZF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Medifocus Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Medifocus, Inc. (QX) News Articles